2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114118S1
    Semaglutide-d8 tetraTFA 99.87%
    Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
    Semaglutide-d8 tetraTFA
  • HY-N0229S13
    L-Alanine-d7 74280-71-0 99.83%
    L-Alanine-d7 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-d7
  • HY-N0473S15
    L-Tyrosine-d3 71939-39-4 99.92%
    L-Tyrosine-d3 is the deuterium labeled L-Tyrosine. L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.
    L-Tyrosine-d3
  • HY-W015309S
    Decanoic acid-d3 102611-15-4 ≥99.0%
    Decanoic acid-d3 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects.
    Decanoic acid-d3
  • HY-13918
    Etimizol 64-99-3
    Etimizol(Ethymisole; Antiffine; Ethylnorantifein) was shown to relieve amnesia effectively in the origin of which there is the hypoxic component (hypobaric hypoxia, actinomycin D, mechanical injury of the brain). Etimizol can decrease the K-+ permeability of neurons' membrane during action potential.
    Etimizol
  • HY-17554
    (R)-Oxiracetam 68252-28-8 99.88%
    (R)-Oxiracetam is the (R)-enantiomer of the nootropic drug oxiracetam.
    (R)-Oxiracetam
  • HY-41268
    3-Methoxyphenylethylamine 2039-67-0 99.39%
    3-Methoxyphenylethylamine is an organic compound that is used as an intermediate for pharmaceuticals, dyestuffs, and liquid crystal materials.
    3-Methoxyphenylethylamine
  • HY-70020
    Cevimeline 107233-08-9 99.88%
    Cevimeline (AF-102B) is a quinuclidine derivative of acetylcholine and a selective and orally active muscarinic M1 and M3 receptor agonist. Cevimeline stimulates secretion by the salivary glands and can be used as a sialogogue for xerostomia. Cevimeline can cross the blood-brain barrier (BBB).
    Cevimeline
  • HY-B1283
    Mephenesin 59-47-2 99.69%
    Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm.
    Mephenesin
  • HY-B1397
    Cyclizine 82-92-8 98.64%
    Cyclizine, a piperazine-derivative, is a potent and selective histamine H1 receptor antagonist. Cyclizine can be used for the research of nausea, vomiting, and dizziness.
    Cyclizine
  • HY-B1895
    Levodropropizine 99291-25-5 99.89%
    Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent.
    Levodropropizine
  • HY-N6829
    Retusin 1245-15-4 ≥99.0%
    Retusin (Quercetin-3,3',4',7-tetramethylether) is a tyrosinase inhibitor, with IC50 values of 50.9 μM and 51.8 μM against mushroom and intracellular tyrosinase, respectively. Retusin also acts as a free radical scavenger, melanogenesis inhibitor, anti-apoptosis agent, neuroprotective agent, antiemetic, antifungal agent, and antiviral agent. Retusin scavenges ABTS•+ and DPPH• free radicals. Retusin can be used in studies related to hyperpigmentation, vomiting, Aspergillus niger infection, and COVID-19 infection.
    Retusin
  • HY-100928
    YS 035 hydrochloride 89805-39-0 99.15%
    YS 035 hydrochloride is a Ca2+ antagonist on cellular uptake and mitochondrial efflux of calcium ions. YS 035 hydrochloride inhibits Ca2+ uptake by muscle cells and inhibits Na+/Ca2+ exchange (Ki=28 µM). YS 035 hydrochloride is a useful tool for research on the mitochondrial Ca2+ transport.
    YS 035 hydrochloride
  • HY-110131
    A 85380 hydrochloride 174740-86-4
    A 85380 hydrochloride is a novel, high affinity neuronal nicotinic acetylcholine receptor (nAChR) agonist. A 85380 hydrochloride exhibits selectivity for the α4β2 nAChR subtypes. A 85380 hydrochloride has a broad-spectrum analgesic profile.
    A 85380 hydrochloride
  • HY-117173
    (Rac)-Rasagiline 1875-50-9
    (Rac)-Rasagiline (AGN1135) is the racemate of Rasagiline. (Rac)-Rasagiline is a selective type B MAO (MAO-B) inhibitor. (Rac)-Rasagiline can be used for Parkinson's disease research. (Rac)-Rasagiline protects against MPTP (HY-15608)-induced toxicity.
    (Rac)-Rasagiline
  • HY-117699
    Fluanisone 1480-19-9 99.89%
    Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia.
    Fluanisone
  • HY-119594
    Melarsoprol 494-79-1 98.0%
    Melarsoprol, a melaminophenylarsine-type trivalent organic arsenical, is an important agent for African trypanosomiasis. Melarsoprol inhibits the growth of lymphoid leukemic cell by inducing apoptosis. Melarsoprol crosses the blood-brain barrier.
    Melarsoprol
  • HY-122805
    PF-794 2056111-45-4 99.19%
    PF-794 is a potent, selective and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with an IC50 of 39 nM. PF-794 shows selective for the TNIK family. PF-794 reduces endogenous p120-catenin phosphorylation in cells. PF-794 can be used for teh study of psychiatric disorders.
    PF-794
  • HY-125036
    MitoBloCK-11 413606-16-3 99.06%
    MitoBloCK-11 is a new small molecule with a protein-binding target, Seo1. MitoBloCK-11 plays an important role in the delivery of PINK1 pathway. MitoBloCK-11 can be used in the study of autosomal recessive Parkinson's disease.
    MitoBloCK-11
  • HY-126049
    (S)-Oxiracetam 88929-35-5 99.56%
    (S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke.
    (S)-Oxiracetam
Cat. No. Product Name / Synonyms Application Reactivity